Document Type : Original Article
Authors
1
Chemistry of Natural and Microbial Products Dept., Pharmaceutical Industries Div., National Research Centre, 33 EL Bohouth St., Dokki, 12622, Giza, Egypt.
2
Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef, 62511, Egypt.
Abstract
Actinomycetes found in symbiosis with marine sponges have the potential to yield new effective pharmaceuticals, such as antifungal, antibiotic, anticancer, and antiviral compounds. This study aims to identify bioactive metabolites from these actinomycetes. Biologically guided screening for antifungal and cytotoxic activity of isolated actinomycetes revealed that 37 species exhibited a broad spectrum of potency as antifungal, anticancer, antioxidants, and antibiotics. The promising isolate was phenotypically and genotypically identified as Streptomyces acrimycini strain MBS-HRS-EG (MYI1) (ID: PP477812.1). In vitro, assessment of strain MBS-HRS-EG exhibited a broad spectrum of antifungal potency against fungal pathogens such as Candida albicans, Candida tropicalis, Aspergillus Niger, Fusarium oxisporium, Fusarium solani, and Rhizoctonia solani by 12, 19, 16, 17, 21, and 18 mm, respectively. The fermentation broth of the selected strain has a broad-spectrum potency as an antibacterial effect against gram-positive pathogenic bacteria like Bacillus cereus, Staphylococcus aureus, and Streptococcus pyogenes by 16, 19, and 26 mm, respectively.
Additionally, it showed activity against gram-negative bacteria such as Escherichia coli, Klebsiella Pneumonia, and Pseudomonas aeruginosa by 15, 19, and 20 mm, respectively. The results of the DPPH radical scavenging activities showed that the radical scavenging activity was 95.61%, closest to the reference ascorbic acid at 99.84%. Chemical profiling of the strain fermentation broth was conducted using UHPLC-QTOF-MS/MS. The produced secondary metabolites were identified using MS DIAL. Confirmation of the UHPLC/QTOF MS analysis data for the bioactive actinomycetes metabolites was done by comparing their analysis data with identified compounds presented in the DNP database and available database of ordinary products to find the nearest matches for the detected metabolites. The analysis identified 21 bioactive metabolites, including macrolide antibiotics such as Natamycin, Strevertene A, Albocyclin, Bafilomycin D with antifungal activity, cyclic peptides like Maculosin, macrocyclic peptides such as Microsclerodermin D, angucyclic antibiotics like Landomycin H with antifungal, anticancer, and antibiotic properties, polyketides such as Delactonmycin with antiviral activity, and lipodepsipeptide like Viridamide A with antiprotozoal activity. The results concluded that the potent strain can be applied to produce various pharmaceutical products
Keywords
Main Subjects
)
View on SCiNiTO